reptides › weight loss › survodutide

survodutide

boehringer and zealand's glucagon/GLP-1 dual agonist. 16.6% weight loss in the SYNCHRONIZE-1 phase 3, and a standout liver result. investigational, not approved.

tier A · weight loss · 16.6% SYNCHRONIZE-1 phase 3

verdict

a GLP-1 plus glucagon dual agonist with phase 3 obesity data and a breakthrough-tier liver story. still investigational, not FDA-approved.

if you're asking whether survodutide works for weight — SYNCHRONIZE-1, the pivotal phase 3 obesity trial (n=726, 76 weeks), reported about 16.6% mean weight loss at the top dose, results presented at ADA in June 2026 and published in NEJM. that lands below retatrutide's phase 3 number and roughly in tirzepatide's range, with the open question being how the glucagon arm trades off against tolerability over time. the approval call belongs to the full phase 3 package, not to gray-market reports.

if you came in for the liver angle — this is survodutide's clearest differentiator. in the phase 2 MASH trial (n=295, 48 weeks), up to about 62% of participants in the 4.8mg arm achieved MASH improvement without worsening of fibrosis, versus 5% on placebo. that is improvement, not resolution, and it earned the molecule FDA Breakthrough Therapy designation for non-cirrhotic MASH in September 2024. the confirmatory phase 3 LIVERAGE program is still enrolling and will not read out for years.

if you're asking about gray-market survodutide — pre-approval, peptide-vendor channel only. no GMP, no FDA-reviewed label, no supervised titration. the glucagon receptor arm raises heart rate and resting energy expenditure, which is part of the mechanism and part of the risk. sourcing, identity, and concentration are unverified outside the trial supply chain.

based on published evidence and disclosed clinical practice. not medical advice. dose and protocol conversations belong with a clinician.

why A-tier

survodutide has a published phase 3 obesity result (SYNCHRONIZE-1: about 16.6% weight loss over 76 weeks) and a phase 2 MASH signal strong enough to earn FDA Breakthrough Therapy designation. that is real, late-stage clinical evidence, which puts it firmly in A territory. it lands below retatrutide (S, deeper phase 3 weight loss) because the obesity number is more modest and it remains investigational with no approval and confirmatory MASH outcomes still years out. graded on merit: strong data, narrow no-label status.

the core tension

survodutide is two stories in one molecule. The obesity number (about 16.6% in SYNCHRONIZE-1) is good but sits below retatrutide and near tirzepatide. The liver story (a Breakthrough Therapy tag for MASH) is where it stands apart. The question is whether the glucagon arm's energy-expenditure and hepatic benefits justify the tolerability tradeoff once the confirmatory data is in.

what it is

A 29-amino-acid investigational dual agonist. Activates the GLP-1 receptor and the glucagon receptor at once. Boehringer Ingelheim and Zealand Pharma, development code BI 456906. The novel piece is glucagon agonism, the hormone that raises blood sugar. Paired with GLP-1, it drives lipolysis, resting energy expenditure, and direct hepatic fat oxidation without the hyperglycemia glucagon alone would cause. This is a dual agonist, GLP-1 plus glucagon, not a triple agonist like retatrutide.

what it does

The GLP-1 arm delivers appetite suppression and glucose control in the incretin-class style. The glucagon arm adds energy expenditure and a direct effect on the liver. SYNCHRONIZE-1 (phase 3, presented at ADA June 2026, published in NEJM): about 16.6% mean weight loss over 76 weeks in adults with overweight or obesity without diabetes. The phase 2 MASH trial: up to ~62% of the 4.8mg arm reached MASH improvement without worsening of fibrosis at 48 weeks.

origin

Built inside Boehringer Ingelheim's metabolic pipeline under a collaboration with Zealand Pharma, the Danish peptide house behind the dual-agonist chemistry. Phase 2 obesity data landed in The Lancet (2023); phase 2 MASH data in NEJM (2024). The molecule carries FDA Breakthrough Therapy designation (September 2024) and Fast Track for non-cirrhotic MASH. The global phase 3 program runs the SYNCHRONIZE obesity trials and the LIVERAGE MASH trials. SYNCHRONIZE-1 read out in 2026. The confirmatory MASH outcomes trials are event-driven and run for years.

why researchers are interested

Two things draw attention. First, a glucagon/GLP-1 dual agonist is mechanistically distinct from the GIP/GLP-1 drugs (tirzepatide) that dominate the market, so it offers a different lever. Second, the liver result is genuinely strong: a Breakthrough Therapy tag for non-cirrhotic MASH is not handed out casually. The peptide community tracks it as a credible next-generation entry rather than a sure thing.

does it work

Yes on the evidence so far, with the standard pre-approval caveats. SYNCHRONIZE-1 is a real phase 3 obesity result (about 16.6% at 76 weeks), not a projection. The MASH phase 2 signal is among the stronger liver readouts in the class. Open questions: the glucagon arm's heart-rate and long-term cardiovascular profile, gastrointestinal tolerability across the titration, and the confirmatory MASH outcomes that have not read out. The approval call belongs after the full phase 3 package, not the gray market.

claims vs the data

  • matches tirzepatide for weight loss — partially true — SYNCHRONIZE-1 reported about 16.6% over 76 weeks, in tirzepatide's general range but no published head-to-head exists.
  • beats retatrutide for weight loss — contradicted — retatrutide's phase 3 (TRIUMPH-1) reached 28.3% at 80 weeks. survodutide's phase 3 obesity number is lower.
  • reverses liver disease (MASH) — partially true — phase 2 showed MASH improvement without worsening of fibrosis in up to ~62% of the 4.8mg arm. that is improvement, not resolution, and confirmatory phase 3 outcomes are pending.
  • glucagon agonism boosts metabolism — supported — the glucagon arm raises resting energy expenditure and drives hepatic fat oxidation, the mechanistic basis for the liver effect.
  • FDA approved for MASH — contradicted — survodutide holds Breakthrough Therapy designation and Fast Track for non-cirrhotic MASH. neither is approval; it is investigational.
  • as well tolerated as GLP-1 monotherapy — unverified — GI side effects are class-typical and the glucagon arm adds heart-rate elevation. full-titration tolerability is an open phase 3 question.
  • will be approved soon — weak — no approval date has been confirmed. confirmatory MASH outcomes trials are event-driven and run for years.

key facts

  • molecular formula: C₁₉₂H₂₈₉N₄₇O₆₁
  • molecular weight: ~4232 g/mol
  • amino acids: 29
  • half-life: ~6 days
  • type: GLP-1/glucagon dual agonist
  • CAS: 2805997-46-8
  • 16.6% avg weight loss, 76wk (SYNCHRONIZE-1)
  • ~62% MASH improvement, 4.8mg (phase 2)
  • Breakthrough FDA therapy tag, non-cirrhotic MASH
  • 29 aa GLP-1 + glucagon dual agonist

frequently asked questions

What is survodutide?

Survodutide is an investigational dual agonist peptide that activates the GLP-1 receptor and the glucagon receptor. Developed by Boehringer Ingelheim and Zealand Pharma (code BI 456906), it is in phase 3 clinical trials for obesity and in development for metabolic dysfunction-associated steatohepatitis (MASH) as of June 2026.

What does survodutide do?

Survodutide combines GLP-1 appetite suppression and glucose control with glucagon-receptor activation, which raises energy expenditure and acts directly on the liver. In the SYNCHRONIZE-1 phase 3 obesity trial it produced about 16.6% mean weight loss over 76 weeks (presented at ADA, June 2026). In a phase 2 MASH trial, up to about 62% of the 4.8mg arm achieved MASH improvement without worsening of fibrosis.

How does survodutide work?

Survodutide is a dual agonist. The GLP-1 arm slows digestion and suppresses appetite. The glucagon arm raises resting energy expenditure and drives hepatic fat oxidation directly, which is the basis for its strong liver-fat effect. Unlike tirzepatide (GIP plus GLP-1) or retatrutide (GIP plus GLP-1 plus glucagon), survodutide targets GLP-1 plus glucagon only.

How is survodutide typically administered?

Survodutide is administered as a once-weekly subcutaneous injection in clinical trials, with stepwise dose titration. Final dosing protocols are being determined by the ongoing phase 3 program. The compound is not commercially available for prescription as of June 2026.

What are the side effects of survodutide?

Reported side effects in clinical trials are primarily gastrointestinal, nausea, vomiting, and diarrhea, consistent with the GLP-1 drug class. The glucagon component adds heart-rate elevation as a class-specific concern, under ongoing evaluation in phase 3. Tolerability over the full titration is one of the open questions for the program.

Is survodutide FDA approved?

No. Survodutide is investigational and in phase 3 clinical trials. It holds FDA Breakthrough Therapy designation (September 2024) and Fast Track status for non-cirrhotic MASH, which can speed review but is not approval. FDA approval would depend on the full phase 3 package and a submitted application.

When will survodutide be FDA approved?

As of June 2026 there is no announced FDA approval date. The SYNCHRONIZE-1 phase 3 obesity trial read out in 2026 (presented at ADA). The confirmatory phase 3 MASH outcomes trials (LIVERAGE program) are event-driven and run for years. Any approval timing depends on the full efficacy and safety package; no date has been confirmed by Boehringer Ingelheim.

How much does survodutide cost?

Survodutide is not commercially available; no clinical retail price exists. On the research-chemical market it tends to price in line with other newer dual-agonist peptides, reflecting synthesis complexity. There is no FDA-reviewed label or supervised dosing for the gray-market product.

related peptides

  • retatrutide — triple-agonist with deeper phase 3 weight loss
  • tirzepatide — GIP/GLP-1 dual agonist, the market benchmark
  • semaglutide — first-gen GLP-1 reference

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.